Study links gestational NSAID use to risk of childhood chronic kidney disease
HQ Team December 28, 2024: A study from Taiwan links the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy, with a potential risk.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team December 28, 2024: A study from Taiwan links the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy, with a potential risk.
Bharti Jayshankar December 28, 2024: A recent research reveals that certain symptoms precede a diagnosis of multiple sclerosis (MS) in pediatric patients. The.
Bharti Jayshankar December 28, 2024: The Centers for Disease Control and Prevention (CDC) has identified mutations in genetic sequences from a patient in.
HQ Team December 28, 2024: Research has shown a potential connection between the progression of Alzheimer’s disease in people who take sleeping pills..
The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death.
Humacyte Global, Inc., a US-based bioengineering company, got the US regulator’s nod for its product Symvess, a surgical implant to replace a patient’s.
fizer Inc.’s combination drug to treat a type of metastatic colorectal cancer has been approved by the US drug regulator, according to a.
Vertex Pharmaceuticals Inc.’s Alyftrek drug got clearance from the Food and Drug Administration to expand its treatment for cystic fibrosis in people six.
Danish pharmaceutical company Novo Nordisk’s combination drug achieved a 22.7% weight-loss reduction compared to a dummy drug during end-stage trials, according to a.
The US Food and Drug Administration has approved Ionis Pharmaceuticals’ drug to treat a rare and life-threatening genetic disease known as familial chylomicronemia.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com